我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
21
8 进行中
药物批准
23
批准总数
监管机构
4
监管机构数
成立时间
1983
进行中（未招募）
2
9.5%
已完成
8
38.1%
尚未招募
6
28.6%
招募中
5
23.8%
NMPA
National Medical Products Administration
FDA
Food and Drug Administration
PHILIPPINES
Philippines FDA
SFDA
Saudi Food and Drug Authority
13
- The Indian Council of Medical Research (ICMR) has licensed three indigenous biomedical technologies to Emcure Pharmaceuticals and Biological E under its Medical Innovations Patent Mitra initiative. - SHetA2, a first-in-class anti-HPV therapeutic candidate for Cervical Intraepithelial Neoplasia (CIN), was licensed to Emcure Pharmaceuticals for further development and commercialization. - Two next-generation vaccine technologies targeting Salmonella typhi, Salmonella paratyphi, and Shigella infections were licensed to Biological E Ltd., developed at ICMR-NIRBI, Kolkata. - The technology transfers aim to accelerate publicly funded research into affordable healthcare solutions and strengthen India's biomedical innovation ecosystem.
